<p>如果你在 20 多岁，你可能还有超过四十年的时间可以投资，直到退休。有些人可能会建议现在是采取激进投资立场的时候，但这可能意味着比你想象的更大的风险。对错误的股票进行大额投资，你可能会把数千美元变成几分钱。</p>
<p>一个更合理的选择可能是寻找一组在本质上具有增长潜力的行业领导者进行投资。医疗保健行业就是一个很好的例子，因为每个人都需要医疗服务，而技术进步推动了该行业的增长。而且，幸运的是，行业领导者 <strong>Medtronic</strong>(MDT -0.71%)、<strong>Johnson &amp; Johnson</strong>(JNJ -0.57%) 和 <strong>Merck</strong>(MRK 0.34%) 目前的价格都很有吸引力。</p>
<p>以下是年轻投资者可能想要购买这三只医疗保健股票的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1OTEvMjFfMTFfMTEtYS1wZXJzb24tcG9pbnRpbmctdG8tYS13cmlzdHdhdGNoLV9nZXR0eWltYWdlcy0xMTc1MjA1OTA0LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1OTEvMjFfMTFfMTEtYS1wZXJzb24tcG9pbnRpbmctdG8tYS13cmlzdHdhdGNoLV9nZXR0eWltYWdlcy0xMTc1MjA1OTA0LmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. Medtronic 正在进行一些正常的维护</h2>
<p>Medtronic 是全球最大的医疗设备制造商之一。它在心血管、神经科学、外科医疗和糖尿病领域占据行业领先地位。公司的增长停滞不前。这使得华尔街对其股票持悲观态度，股价比 2021 年的高点下跌了约 30%。目前的股息收益率接近历史高点，约为 3%。</p>
<p>为什么要购买这只低迷的股票？因为 Medtronic 有着在每家公司最终都必须面对的艰难时期中生存下来的悠久历史。其连续 48 年的年度股息增长就是证明。这是一个令人难以置信的记录，使得该公司距离股息之王的地位仅差两年。然而，更重要的是，管理层正在采取必要措施来改善盈利能力。这包括削减成本、投资新技术和产品，以及将业务重心重新聚焦于最盈利的运营。下一步是公司糖尿病业务的分拆，预计将在 2026 年初进行。</p>
<p>如果你不介意从一家懂得如何在艰难时期生存的公司收取高额收益，Medtronic 是一个很好的选择，无论你是 20 岁还是 65 岁。但如果你 20 岁，你可以受益于数十年的业务增长，并利用股息再投资计划进一步复利你的回报。</p>
<h2>2. Johnson &amp; Johnson 将渡过滑石粉危机</h2>
<p>接下来是 Johnson &amp; Johnson，这是一家在制药和医疗设备领域的巨头。与 Medtronic 一样，它在投资者中也不受欢迎。该股票的股息收益率为 3%，处于历史收益范围的高位。平均制药股票的收益率约为 1.4%，而平均医疗保健股票的收益率大约为 1.8%。</p>
<p>然而，股价并没有像 Medtronic 那样低迷，J&amp;J 的股价比历史最高点下跌了大约 5%。不过，这里存在一个实质性的负担，即针对 J&amp;J 提起的滑石粉诉讼。涉及数十亿美元的赔偿，公司无法完全与股东讨论这个问题，因为这是法律性质的问题。这种不确定性使得 J&amp;J 的股票略显疲软。但这位股息之王已经连续六十多年每年增加股息，清楚地表明它知道如何在艰难时期生存。</p>
<p>公平地说，公司核心业务也面临一些逆风。包括专利到期和需要不断推出新药和医疗设备。但这些只是正常的商业波动，类似于 Medtronic 所面临的情况。加上法律问题，可能使得 J&amp;J 更适合激进投资者或那些能够长期持有的投资者，比如 20 多岁的投资者。</p>
<h2>3. Merck 面临专利悬崖</h2>
<p>Medtronic 专注于医疗设备。Johnson &amp; Johnson 的专长是医疗设备和药物。Merck 则专注于药物。尽管它的年度股息增长历史不如前两者长，仅有 15 年，但 Merck 的股息在几十年中总体上呈上升趋势。虽然在股息方面它并不完全与 Medtronic 和 J&amp;J 平起平坐，但它仍然是一家可靠的企业，证明了它能够在艰难时期中生存。</p>
<p>不过，它目前正面临困难。首先，市场对医疗公司的看法相对消极，涉及当前政府的政治和社会问题。考虑到医疗保健的重要性，尤其是药物，这种情况可能会过去。Merck 的第二个问题是，其增长在很大程度上受到一种肿瘤药物 -- Keytruda 的影响。然而，在几年后，这种药物将失去专利保护，Merck 需要有其他药物准备好，以弥补仿制药可能带走的收入。Merck 的产品管线看起来有些薄弱，因此投资者担心它无法应对即将到来的专利悬崖。</p>
<p>这并不是不合理，但 Merck 拥有世界级的研发团队，而且它足够大，可以收购拥有有吸引力产品的小型竞争对手（如果需要的话）。它很可能会找到解决专利问题的方法，就像它以前多次做到的那样。不过，目前投资者情绪低迷，股价比 2024 年的高点下跌了近 40%，而股息收益率则处于历史高位，约为 4%。如果你有时间的优势，可以现在购买，并舒适地等待更好的日子。</p>
<h2>医疗保健故事的关键</h2>
<p>在医疗保健行业有两种主要的投资方式。你可以选择高风险高回报，投资那些拥有新颖产品的小型初创公司，希望你选择的公司能够在市场中获胜。或者，你可以购买那些行业领导者，这些公司已经多次证明它们有能力在长期内生存和发展，通常还会收购初创公司以受益于它们的新产品。</p>
<p>大多数投资者更适合关注行业领导者。而且，通常购买行业领导者的最佳时机是当投资者对其前景感到悲观的时候。今天的情况正是如此，医疗巨头美敦力、强生和默克正面临这样的情形。如果你在 20 多岁时买入并持有直到退休（希望在此期间不断再投资股息），历史表明你将成为一位非常满意的股东。</p>

强生

<p>文章建议 20 多岁的年轻投资者考虑购买三只医疗保健股票：美敦力（Medtronic）、强生（Johnson & Johnson）和默克（Merck）。尽管美敦力最近面临一些困难，但其提供了强劲的股息收益率，并正在重新聚焦于盈利能力。强生虽然面临法律挑战，但在股息增长方面有着悠久的历史。默克主要是一家制药公司，虽然也很可靠，但由于依赖单一药物而面临增长挑战。总体而言，这些股票在医疗保健行业中为长期增长奠定了良好的基础</p>

<p>If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but that could entail more risk than you think. Make a big bet on the wrong stock and you could turn thousands of dollars into pennies.</p>
<div class="lb-trans"><p>如果你在 20 多岁，你可能还有超过四十年的时间可以投资，直到退休。有些人可能会建议现在是采取激进投资立场的时候，但这可能意味着比你想象的更大的风险。对错误的股票进行大额投资，你可能会把数千美元变成几分钱。</p>
</div><p>An alternative path that might make more sense is to find a collection of industry leaders in an inherently growth-oriented industry to invest in. The healthcare industry is a great example, since everyone needs medical care and technological advances drive the sector's growth. And, lucky for you, industry leaders <strong>Medtronic</strong>(MDT -0.71%), <strong>Johnson &amp; Johnson</strong>(JNJ -0.57%), and <strong>Merck</strong>(MRK 0.34%) are all attractively priced right now.</p>
<div class="lb-trans"><p>一个更合理的选择可能是寻找一组在本质上具有增长潜力的行业领导者进行投资。医疗保健行业就是一个很好的例子，因为每个人都需要医疗服务，而技术进步推动了该行业的增长。而且，幸运的是，行业领导者 <strong>Medtronic</strong>(MDT -0.71%)、<strong>Johnson &amp; Johnson</strong>(JNJ -0.57%) 和 <strong>Merck</strong>(MRK 0.34%) 目前的价格都很有吸引力。</p>
</div><p>Here's why younger investors might want to buy all three of these healthcare stocks.</p>
<div class="lb-trans"><p>以下是年轻投资者可能想要购买这三只医疗保健股票的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1OTEvMjFfMTFfMTEtYS1wZXJzb24tcG9pbnRpbmctdG8tYS13cmlzdHdhdGNoLV9nZXR0eWltYWdlcy0xMTc1MjA1OTA0LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828591%2F21_11_11-a-person-pointing-to-a-wristwatch-_gettyimages-1175205904.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. Medtronic is taking care of some normal maintenance</h2>
<div class="lb-trans"><h2>1. Medtronic 正在进行一些正常的维护</h2>
</div><p>Medtronic is one of the largest medical device makers on the planet. It has industry-leading positions in the cardiovascular, neuroscience, medical surgical, and diabetes niches. The company's growth has stalled out. That has left Wall Street downbeat on the shares, which trade down around 30% from their 2021 highs. The dividend yield is near historical highs at around 3%.</p>
<div class="lb-trans"><p>Medtronic 是全球最大的医疗设备制造商之一。它在心血管、神经科学、外科医疗和糖尿病领域占据行业领先地位。公司的增长停滞不前。这使得华尔街对其股票持悲观态度，股价比 2021 年的高点下跌了约 30%。目前的股息收益率接近历史高点，约为 3%。</p>
</div><p>Why buy this down-and-out stock? Because Medtronic has a long history of surviving through the hard times that every company eventually has to face. The proof of this is its 48 consecutive years' worth of annual dividend increases. That's an incredible streak that places the company just two years shy of Dividend King status. More important today, however, is that management is taking the steps necessary to improve profitability. That includes cutting costs, investing in new technologies and products, and refocusing its business around its most profitable operations. The next big move is the spin-off of the company's diabetes business, which is set to take place in early 2026.</p>
<div class="lb-trans"><p>为什么要购买这只低迷的股票？因为 Medtronic 有着在每家公司最终都必须面对的艰难时期中生存下来的悠久历史。其连续 48 年的年度股息增长就是证明。这是一个令人难以置信的记录，使得该公司距离股息之王的地位仅差两年。然而，更重要的是，管理层正在采取必要措施来改善盈利能力。这包括削减成本、投资新技术和产品，以及将业务重心重新聚焦于最盈利的运营。下一步是公司糖尿病业务的分拆，预计将在 2026 年初进行。</p>
</div><p>If you don't mind collecting a lofty yield from a company that knows how to survive hard times, Medtronic is a great pick if you are 20 or 65. But if you are 20, you can benefit from decades of business growth and use a dividend reinvestment plan to further compound your returns.</p>
<div class="lb-trans"><p>如果你不介意从一家懂得如何在艰难时期生存的公司收取高额收益，Medtronic 是一个很好的选择，无论你是 20 岁还是 65 岁。但如果你 20 岁，你可以受益于数十年的业务增长，并利用股息再投资计划进一步复利你的回报。</p>
</div><h2>2. Johnson &amp; Johnson will survive the talcum powder mess</h2>
<div class="lb-trans"><h2>2. Johnson &amp; Johnson 将渡过滑石粉危机</h2>
</div><p>Next up on this list is Johnson &amp; Johnson, which is a giant in both the pharmaceutical and medical device spaces. Like Medtronic, it is out of favor with investors. The stock's dividend yield is 3% and toward the high side of the historical yield range. The average pharmaceutical stock has a yield of around 1.4% while the average healthcare stock's yield is roughly 1.8%.</p>
<div class="lb-trans"><p>接下来是 Johnson &amp; Johnson，这是一家在制药和医疗设备领域的巨头。与 Medtronic 一样，它在投资者中也不受欢迎。该股票的股息收益率为 3%，处于历史收益范围的高位。平均制药股票的收益率约为 1.4%，而平均医疗保健股票的收益率大约为 1.8%。</p>
</div><p>The stock price, however, isn't quite as downtrodden as that of Medtronic, with J&amp;J's price down from its all-time high by roughly 5% or so. That said, there is a material overhang here in the form of talcum powder lawsuits that have been filed against J&amp;J. There are billions of dollars at stake, and the company can't fully discuss the issue with shareholders because of the legal nature of the problem. The uncertainty has left J&amp;J shares to languish a bit. But this Dividend King has increased its dividend annually for over six consecutive decades, showing clearly that it knows how to survive hard times.</p>
<div class="lb-trans"><p>然而，股价并没有像 Medtronic 那样低迷，J&amp;J 的股价比历史最高点下跌了大约 5%。不过，这里存在一个实质性的负担，即针对 J&amp;J 提起的滑石粉诉讼。涉及数十亿美元的赔偿，公司无法完全与股东讨论这个问题，因为这是法律性质的问题。这种不确定性使得 J&amp;J 的股票略显疲软。但这位股息之王已经连续六十多年每年增加股息，清楚地表明它知道如何在艰难时期生存。</p>
</div><p>To be fair, there are also headwinds to deal with in the company's core operations. The list includes patent expirations and the need to keep bringing out new drugs and medical devices. But those are just normal business fluctuations, much like what Medtronic is dealing with. Adding the legal issue probably makes J&amp;J more appropriate for aggressive investors or those who can stick around for a long time. Like investors in their 20's.</p>
<div class="lb-trans"><p>公平地说，公司核心业务也面临一些逆风。包括专利到期和需要不断推出新药和医疗设备。但这些只是正常的商业波动，类似于 Medtronic 所面临的情况。加上法律问题，可能使得 J&amp;J 更适合激进投资者或那些能够长期持有的投资者，比如 20 多岁的投资者。</p>
</div><h2>3. Merck has a patent cliff coming up</h2>
<div class="lb-trans"><h2>3. Merck 面临专利悬崖</h2>
</div><p>Medtronic is focused on medical devices. Johnson &amp; Johnson's specialties are medical devices and drugs. Merck is just drugs. And while it doesn't have as long a history of annual dividend increases, at just 15 years, Merck's dividend has trended generally higher for decades. It doesn't exactly stand toe to toe with Medtronic and J&amp;J on the dividend front, but it is still a reliable business that has proven it can muddle through hard times.</p>
<div class="lb-trans"><p>Medtronic 专注于医疗设备。Johnson &amp; Johnson 的专长是医疗设备和药物。Merck 则专注于药物。尽管它的年度股息增长历史不如前两者长，仅有 15 年，但 Merck 的股息在几十年中总体上呈上升趋势。虽然在股息方面它并不完全与 Medtronic 和 J&amp;J 平起平坐，但它仍然是一家可靠的企业，证明了它能够在艰难时期中生存。</p>
</div><p>It is facing a hard time right now. First, there's a rather negative view of healthcare companies in the market related to political and social issues involving the current administration. Given the importance of healthcare in general, and drugs in particular, this will likely pass. The second problem for Merck is that its growth is heavily influenced by one oncology drug -- Keytruda. In a few years, however, this drug will lose patent protections and Merck will need to have other drugs lined up to make up for the revenue that generic drugs tend to steal away. Merck's pipeline looks a bit weak, so investors are worried it won't be ready for the approaching patent cliff.</p>
<div class="lb-trans"><p>不过，它目前正面临困难。首先，市场对医疗公司的看法相对消极，涉及当前政府的政治和社会问题。考虑到医疗保健的重要性，尤其是药物，这种情况可能会过去。Merck 的第二个问题是，其增长在很大程度上受到一种肿瘤药物 -- Keytruda 的影响。然而，在几年后，这种药物将失去专利保护，Merck 需要有其他药物准备好，以弥补仿制药可能带走的收入。Merck 的产品管线看起来有些薄弱，因此投资者担心它无法应对即将到来的专利悬崖。</p>
</div><p>That's not unreasonable, but Merck has world-class R&amp;D teams, and it is large enough to buy smaller competitors with attractive products (if it needs to). It is highly likely that it figures out how to deal with the patent issue, like it has many times before. Still, investors are downbeat at the moment, and the stock is off its 2024 highs by nearly 40% and the dividend yield is a historically high 4% or so. If you have the benefit of time, you can buy now and comfortably wait for better days.</p>
<div class="lb-trans"><p>这并不是不合理，但 Merck 拥有世界级的研发团队，而且它足够大，可以收购拥有有吸引力产品的小型竞争对手（如果需要的话）。它很可能会找到解决专利问题的方法，就像它以前多次做到的那样。不过，目前投资者情绪低迷，股价比 2024 年的高点下跌了近 40%，而股息收益率则处于历史高位，约为 4%。如果你有时间的优势，可以现在购买，并舒适地等待更好的日子。</p>
</div><h2>The key to the healthcare story</h2>
<div class="lb-trans"><h2>医疗保健故事的关键</h2>
</div><p>There are two broad ways to play the healthcare sector. You can swing for the fences and buy small upstarts with novel products, hoping that the companies you pick are the ones that end up winning in the market. Or you can buy industry leaders that have proven time and again that they have the wherewithal to survive and thrive over the long term, often buying up the upstarts to benefit from their novel products.</p>
<div class="lb-trans"><p>在医疗保健行业有两种主要的投资方式。你可以选择高风险高回报，投资那些拥有新颖产品的小型初创公司，希望你选择的公司能够在市场中获胜。或者，你可以购买那些行业领导者，这些公司已经多次证明它们有能力在长期内生存和发展，通常还会收购初创公司以受益于它们的新产品。</p>
</div><p>Most investors will be better off focusing on the industry leaders. And, often, the best time to buy industry leaders is when investors are downbeat on their prospects. Which is exactly the case today with industry giants Medtronic, Johnson &amp; Johnson, and Merck. If you buy in while you are in your 20s and hold until you retire (hopefully reinvesting dividends all along the way), history suggests you will end up a very happy shareholder.</p>
<div class="lb-trans"><p>大多数投资者更适合关注行业领导者。而且，通常购买行业领导者的最佳时机是当投资者对其前景感到悲观的时候。今天的情况正是如此，医疗巨头美敦力、强生和默克正面临这样的情形。如果你在 20 多岁时买入并持有直到退休（希望在此期间不断再投资股息），历史表明你将成为一位非常满意的股东。</p>
</div>

如果你处于 20 多岁的年龄段，可以考虑购买这三只医疗保健股票